BioSpace News Archive

Dr. Sundy brings deep expertise in translational medicine and innovative drug development from leadership role at Gilead

58% complete response rate reported for patients with relapsed/refractory MCL, with a median follow-up of 8.3 months 100% progression-free survival reported for patients with CLL, with a median follow-up of 12.8 months Cirmtuzumab continued to be well tolerated in this trial SAN DIEGO--( BUSINESS WIRE )-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel

Aduro Biotech, Inc. (NASDAQ: ADRO), a clinical-stage biopharmaceutical company focused on developing therapies targeting the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand (APRIL) pathways for the treatment of cancer, autoimmune and inflammatory diseases, today announced that the company will host a live conference call and webcast on Monday, June 8, 2020 at 1:00 pm PDT to report data in healthy volunteers from the

Tyme Technologies, Inc. (NASDAQ:TYME) , an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that leadership will participate at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020. The Company will present its corporate overview for 2020 with a special focus on multiple growth opportunities driven by advances in the science of cancer metabolism, pivotal trials in

Study Suggests That Type I IFN Deficiency in the Blood Could Help Define a High-Risk Population

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced the appointment of Herbert Harris, M.D., Ph.D., as its new Executive Vice President, Translational Medicine, effective May 15, 2020.

TIBSOVO® Is the First and Only IDH1 Inhibitor to Be Evaluated in a Phase 3 Clinical Trial for IDH1-Mutant Cholangiocarcinoma

Organicell Regenerative Medicine, Inc., a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that on May 11, 2020, the U.S. Food and Drug Administration authorized two Emergency Compassionate Use Investigational New Drug applications, each for a single patient severely ill from COVID-19.

Financing to Support Modular Presbyopia-Correcting Accommodating Intraocular Lens Technology

Acceleron to host an investor and analyst webcast and conference call following the virtual ATS 2020 presentation on June 24th